Hui, D., Darke, A. K., Guthrie, K. A., Subbiah, I. M., Unger, J. M., Hershman, D. L., Krouse, R. S., Bakitas, M., & O’Rourke, M. A. (2022). Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. JCO Oncology Practice, 18(4), e442–e451. https://doi.org/10.1200/op.21.00407

Nauman, G., Danzl, N. M., Lee, J., Borsotti, C., Madley, R., Fu, J., Hölzl, M. A., Dahmani, A., Dorronsoro Gonzalez, A., Chavez, É., Campbell, S. R., Yang, S., Satwani, P., Liu, K., & Sykes, M. (2022). Defects in Long-Term APC Repopulation Ability of Adult Human Bone Marrow Hematopoietic Stem Cells (HSCs) Compared with Fetal Liver HSCs. The Journal of Immunology, 208(7), 1652–1663. https://doi.org/10.4049/jimmunol.2100966

Bartolomé, A., Suda, N., Yu, J., Zhu, C., Son, J., Ding, H., Califano, A., Accili, D., & Pajvani, U. B. (2022). Notch-mediated Ephrin signaling disrupts islet architecture and β cell function. JCI Insight, 7(6). https://doi.org/10.1172/jci.insight.157694

Obradovic, A., Shen, Y., Sykes, M., & Fu, J. (2021). Integrated analysis toolset for defining and tracking alloreactive T-cell clones after human solid organ and hematopoietic stem cell transplantation. Software Impacts, 10, 100142. https://doi.org/10.1016/j.simpa.2021.100142

Pumpalova, Y. S., Ayeni, O. A., Chen, W. C., Buccimazza, I., Cačala, S., Stopforth, L. W., Farrow, H. A., Mapanga, W., Nietz, S., Phakathi, B., Joffe, M., McCormack, V., Jacobson, J. S., Crew, K. D., Neugut, A. I., Ruff, P., Cubasch, H., & O’Neil, D. S. (2022). The Impact of Breast Cancer Treatment Delays on Survival Among South African Women. The Oncologist, 27(3), e233–e243. https://doi.org/10.1093/oncolo/oyab054

Kasper, B., D’Ambrosio, L., Davis, E. J., Ingham, M., Broto, J. M., Trent, J. C., van Houdt, W. J., & Van Tine, B. A. (2022). What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? Current Treatment Options in Oncology, 23(3), 439–449. https://doi.org/10.1007/s11864-021-00928-y

Chawla, G. S., Tolu, S. S., & Arora, S. (2022). Progression of untreated gastric and pulmonary metastasis in a patient with resected acral melanoma. BMJ Case Reports, 15(3), e247683. https://doi.org/10.1136/bcr-2021-247683

Wright, J. D., Huang, Y., Li, A. H., Melamed, A., & Hershman, D. L. (2022). Nationwide Estimates of Annual Inpatient and Outpatient Hysterectomies Performed in the United States. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000004679

Bansal, R., Park, H., Taborda, C. C., Gordillo, C., Mapara, M. Y., Assal, A., Uhlemann, A.-C., & Reshef, R. (2022). Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 28(3), 135–144. https://doi.org/10.1016/j.jtct.2021.12.015

Maniar, A., Haslam, A., & Prasad, V. (2022). Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 164, 95–104. https://doi.org/10.1016/j.ejca.2022.01.006

Gregory, G. P., Kumar, S., Wang, D., Mahadevan, D., Walker, P., Wagner-Johnston, N., Escobar, C., Bannerji, R., Bhutani, D., Chang, J., Hernandez-Ilizaliturri, F. J., Klein, A., Pagel, J. M., Rybka, W., Yee, A. J., Mohrbacher, A., Huang, M., Farooqui, M., Marinello, P., & Quach, H. (2022). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 6(4), 1232–1242. https://doi.org/10.1182/bloodadvances.2021005872

Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022). Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma Myeloma and Leukemia, 22(7), 442–459. https://doi.org/10.1016/j.clml.2022.01.009

Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., Miller, A., Zhang, X., Lynch, J., Kim, D., Ribeil, J.-A., Asmal, M., Goyal, S., Thompson, A. A., & Tisdale, J. F. (2022). Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 386(7), 617–628. https://doi.org/10.1056/nejmoa2117175

Troy, C., Gill, B. J. A., Miller, M. L., Hickman, R. A., Canoll, P., Zacharoulis, S., Feldstein, N. A., & Bruce, J. N. (2022). Adenocarcinoma Arising in a Yolk Sac Tumor of the Pineal Gland. Journal of Neuropathology & Experimental Neurology, 81(4), 291–295. https://doi.org/10.1093/jnen/nlac002

Viny, A. D. (2021). DNMT3A-Mutant Leukemia Cells Primed to “Fork It Over” under DNA Damage. Clinical Cancer Research, 28(4), 573–575. https://doi.org/10.1158/1078-0432.ccr-21-3949

Shabbir, A., Kojadinovic, A., Gidfar, S., & Mundi, P. S. (2022). Extranodal Diffuse Large B-Cell Lymphoma of Bone and Soft Tissue Presenting With Marked Lymphedema and Hypercalcemia. Cureus. https://doi.org/10.7759/cureus.22025

Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., Wu, J., Dubensky, T. W., McWhirter, S. M., Müller, T., Nair, N., & Luke, J. J. (2021). Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 28(4), 677–688. https://doi.org/10.1158/1078-0432.ccr-21-1963

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O’Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., … Woyach, J. A. (2021). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603–608. https://doi.org/10.1158/1078-0432.ccr-21-1237

Moy, R. H., Walch, H. S., Mattar, M., Chatila, W. K., Molena, D., Strong, V. E., Tang, L. H., Maron, S. B., Coit, D. G., Jones, D. R., Hechtman, J. F., Solit, D. B., Schultz, N., de Stanchina, E., & Janjigian, Y. Y. (2022). Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00242

Menghrajani, K., Gomez-Arteaga, A., Madero-Marroquin, R., Zhang, M.-J., Bo-Subait, K., Sanchez, J., Wang, H.-L., Aljurf, M., Assal, A., Bacher, V. U., Badawy, S. M., Bejanyan, N., Bhatt, V. R., Bredeson, C., Byrne, M., Castillo, P., Cerny, J., Chhabra, S., Ciurea, S. O., … Saber, W. (2022). Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 6(3), 828–847. https://doi.org/10.1182/bloodadvances.2021004881

Kishore, S. A., Bajwa, R., Van Doren, L., Wilkins, C., & O’Sullivan, G. J. (2022). Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population. Current Oncology Reports, 24(3), 351–362. https://doi.org/10.1007/s11912-022-01191-6

Lopez-Bujanda, Z. A., Haffner, M. C., Chaimowitz, M. G., Chowdhury, N., Venturini, N. J., Patel, R. A., Obradovic, A., Hansen, C. S., Jacków, J., Maynard, J. P., Sfanos, K. S., Abate-Shen, C., Bieberich, C. J., Hurley, P. J., Selby, M. J., Korman, A. J., Christiano, A. M., De Marzo, A. M., & Drake, C. G. (2021). Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nature Cancer, 2(8), 803–818. https://doi.org/10.1038/s43018-021-00227-3

Kalani Roy, M., La Carpia, F., Cendali, F., Fernando, S., Moriconi, C., Wojczyk, B. S., Wang, L., Nemkov, T., Hod, E. A., & D’Alessandro, A. (2022). Irradiation Causes Alterations of Polyamine, Purine, and Sulfur Metabolism in Red Blood Cells and Multiple Organs. Journal of Proteome Research, 21(2), 519–534. https://doi.org/10.1021/acs.jproteome.1c00912

Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., Tanoli, Z., Jafari, M., Wan, F., Li, S., Xiong, Y., Duran-Frigola, M., Bertoni, M., Badia-i-Mompel, P., Mateo, L., … Califano, A. (2022). A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Reports Medicine, 3(1), 100492. https://doi.org/10.1016/j.xcrm.2021.100492

Hawley, J. E., Pan, S., Kandadi, H., Chaimowitz, M. G., Sheikh, N., & Drake, C. G. (2021). Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T. JNCI: Journal of the National Cancer Institute, 114(2), 314–317. https://doi.org/10.1093/jnci/djab145

Sidana, S., Kumar, S., Fraser, R., Estrada-Merly, N., Giralt, S., Agrawal, V., Anderson, L. D., Aljurf, M., Banerjee, R., Bashey, A., Battiwalla, M., Beitinjaneh, A., Chakraborty, R., Chhabra, S., Dhakal, B., Dholaria, B., Hashmi, S., Janakiram, M., Lee, C., … D’Souza, A. (2022). Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 28(2), 83.e1-83.e9. https://doi.org/10.1016/j.jtct.2021.10.022

Zhou, Z. N., Chen, L., Melamed, A., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Gockley, A., Hershman, D. L., & Wright, J. D. (2022). Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. Gynecologic Oncology, 164(2), 341–347. https://doi.org/10.1016/j.ygyno.2021.12.005

Moy, R. H., Greally, M., Chou, J. F., Li, J., Desai, A. M., Chalasani, S. B., Won, E., Kelsen, D. P., Ilson, D. H., Janjigian, Y. Y., Capanu, M., & Ku, G. Y. (2022). Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 89(2), 255–265. https://doi.org/10.1007/s00280-021-04384-1

Mullangi, S., & Vasan, N. (2022). Genomic Characterization of De Novo Metastatic Breast Cancer. Clinical Breast Cancer, 22(2), 98–102. https://doi.org/10.1016/j.clbc.2021.11.005

Agalliu, I., Lin, W.-K. J., Zhang, J. S., Jacobson, J. S., Rohan, T. E., Adusei, B., Snyper, N. Y. F., Andrews, C., Sidahmed, E., Mensah, J. E., Biritwum, R., Adjei, A. A., Okyne, V., Ainuson-Quampah, J., Fernandez, P., Irusen, H., Odiaka, E., Folasire, O. F., Ifeoluwa, M. G., … Hsing, A. W. (2021). Overall and central obesity and prostate cancer risk in African men. Cancer Causes & Control, 33(2), 223–239. https://doi.org/10.1007/s10552-021-01515-0

Gorin, M. A., Patel, H. D., Rowe, S. P., Hahn, N. M., Hammers, H. J., Pons, A., Trock, B. J., Pierorazio, P. M., Nirschl, T. R., Salles, D. C., Stein, J. E., Lotan, T. L., Taube, J. M., Drake, C. G., & Allaf, M. E. (2022). Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. European Urology Oncology, 5(1), 113–117. https://doi.org/10.1016/j.euo.2021.04.002

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

Drake, C. G., Pachynski, R. K., Subudhi, S. K., McNeel, D. G., Antonarakis, E. S., Bauer, T. M., Lauer, P., Brockstedt, D., Patricia, D., Wade, M., Zudaire, E., Bandyopadhyay, N., Parasrampuria, D. A., Girgis, S., Mason, G. E., Knoblauch, R. E., Stone, N., Infante, J. R., Gottardis, M. M., & Fong, L. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 25(2), 219–228. https://doi.org/10.1038/s41391-021-00402-8

Lombardo, K. A., Obradovic, A., Singh, A. K., Liu, J. L., Joice, G., Kates, M., Bishai, W., McConkey, D., Chaux, A., Eich, M., Rezaei, M. K., Netto, G. J., Drake, C. G., Tran, P., Matoso, A., & Bivalacqua, T. J. (2021). BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. The Journal of Pathology, 256(2), 223–234. Portico. https://doi.org/10.1002/path.5830

Hillyer, G. C., Nazareth, M., Lima, S., Schmitt, K. M., Reyes, A., Fleck, E., Schwartz, G. K., & Terry, M. B. (2021). E-cigarette Use Among Young Adult Patients: The Opportunity to Intervene on Risky Lifestyle Behaviors to Reduce Cancer Risk. Journal of Community Health, 47(1), 94–100. https://doi.org/10.1007/s10900-021-01027-7

Lassman, A. B., Wen, P. Y., van den Bent, M. J., Plotkin, S. R., Walenkamp, A. M. E., Green, A. L., Li, K., Walker, C. J., Chang, H., Tamir, S., Henegar, L., Shen, Y., Alvarez, M. J., Califano, A., Landesman, Y., Kauffman, M. G., Shacham, S., & Mau-Sørensen, M. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research, 28(3), 452–460. https://doi.org/10.1158/1078-0432.ccr-21-2225

Thangaraju, K., Katneni, U., Akpan, I. J., Tanaka, K., Thomas, T., Setua, S., Reisz, J. A., Cendali, F., Gamboni, F., Nemkov, T., Kahn, S., Wei, A. Z., Valk, J. E., Hudson, K. E., Roh, D. J., Moriconi, C., Zimring, J. C., D’Alessandro, A., Spitalnik, S. L., … Buehler, P. W. (2022). The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.817305

Liu, A. W., Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022). Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opinion on Biological Therapy, 22(8), 997–1004. https://doi.org/10.1080/14712598.2022.2031970

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275

Barbaro, M., Blinderman, C. D., Iwamoto, F. M., Kreisl, T. N., Welch, M. R., Odia, Y., Donovan, L. E., Joanta-Gomez, A. E., Evans, K. A., & Lassman, A. B. (2022). Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. Neurology, 98(3). https://doi.org/10.1212/wnl.0000000000013057

Chronister, B. N. C., Wu, T., Santella, R. M., Neugut, A. I., Wolff, M. S., Chen, J., Teitelbaum, S. L., & Parada, H. (2021). Dietary Acid Load, Serum Polychlorinated Biphenyl Levels, and Mortality Following Breast Cancer in the Long Island Breast Cancer Study Project. International Journal of Environmental Research and Public Health, 19(1), 374. https://doi.org/10.3390/ijerph19010374

Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., Buchschacher, G. L., Alekseev, B., Mellado, B., Karaszewska, B., Doss, J. F., Rasuo, G., Datye, A., Mariathasan, S., Williams, P., & Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 28(1), 144–153. https://doi.org/10.1038/s41591-021-01600-6

Christin, J. R., & Shen, M. M. (2022). Modeling tumor plasticity in organoid models of human cancer. Trends in Cancer, 8(3), 161–163. https://doi.org/10.1016/j.trecan.2021.12.004

Doshi, S. D., Oza, J., Remotti, H., Remotti, F., Moy, M. P., Schwartz, G. K., & Ingham, M. (2021). Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma. JCO Precision Oncology, 5, 1–5. https://doi.org/10.1200/po.20.00201

Stonesifer, C. J., Djavid, A. R., Grimes, J. M., Khaleel, A. E., Soliman, Y. S., Maisel-Campbell, A., Garcia-Saleem, T. J., Geskin, L. J., & Carvajal, R. D. (2021). Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.734354

Lieu, Y. K., Liu, Z., Ali, A. M., Wei, X., Penson, A., Zhang, J., An, X., Rabadan, R., Raza, A., Manley, J. L., & Mukherjee, S. (2021). SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences, 119(1). https://doi.org/10.1073/pnas.2111703119

Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N. T. N., Mishra, S., Nguyen, R. H., Reid, S. A., Serrano, O. K., Singh, S. R. K., Venepalli, N. K., Bakouny, Z., Bashir, B., Bilen, M. A., Caimi, P. F., Choueiri, T. K., Dawsey, S. J., Fecher, L. A., … Stratton, C. (2022). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 5(1), e2142046. https://doi.org/10.1001/jamanetworkopen.2021.42046

Rush, R. E., Dannemiller, K. C., Cochran, S. J., Haines, S. R., Acosta, L., Divjan, A., Rundle, A. G., Miller, R. L., Perzanowski, M. S., Croston, T. L., & Green, B. J. (2021). Vishniacozyma victoriae (syn. Cryptococcus victoriae) in the homes of asthmatic and non-asthmatic children in New York City. Journal of Exposure Science & Environmental Epidemiology, 32(1), 48–59. https://doi.org/10.1038/s41370-021-00342-4

Tan, A. R., Chan, N., Kiesel, B. F., Stein, M. N., Moss, R. A., Malhotra, J., Aisner, J., Shah, M., Gounder, M., Lin, H., Kane, M. P., Lin, Y., Ji, J., Chen, A., Beumer, J. H., & Mehnert, J. M. (2021). A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemotherapy and Pharmacology, 89(1), 49–58. https://doi.org/10.1007/s00280-021-04350-x